Aluminum nanoparticles enhance anticancer immune response induced by tumor cell vaccine

Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ (2004) Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 22:403–415

Bianco A, Kostarelos K, Partidos CD, Prato M (2005a) Biomedical applications of functionalised carbon nanotubes. Chem Commun (Camb) 5:571–577

Bianco A, Kostarelos K, Prato M (2005b) Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol 9:674–679

Cai D, Mataraza JM, Qin ZH, Huang Z, Huang J, Chiles TC, Carnahan D, Kempa K, Ren Z (2005) Highly efficient molecular delivery into mammalian cells using carbon nanotube spearing. Nat Methods 2:449–454

Copier J, Dalgleish A (2006) Overview of tumor cell-based vaccines. Int Rev Immunol 25:297–319

Elder JB, Liu CY, Apuzzo ML (2008) Neurosurgery in the realm of 10(-9), part 2: applications of nanotechnology to neurosurgery—present and future. Neurosurgery 62:269–284, discussion 284-5

Emens LA (2006) Roadmap to a better therapeutic tumor vaccine. Int Rev Immunol 25:415–443

Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 103:6315–6320

Fenske DB, Cullis PR (2008) Liposomal nanomedicines. Expert Opin Drug Deliv 5:25–44

Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, McKenzie IF, Plebanski M (2004) Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 173:3148–3154

Frey A, Mantis N, Kozlowski PA, Quayle AJ, Bajardi A, Perdomo JJ, Robey FA, Neutra MR (1999) Immunization of mice with peptomers covalently coupled to aluminum oxide nanoparticles. Vaccine 17:3007–3019

Hartman KB, Wilson LJ, Rosenblum MG (2008) Detecting and treating cancer with nanotechnology. Mol Diagn Ther 12:1–14

Heller DA, Jeng ES, Yeung TK, Martinez BM, Moll AE, Gastala JB, Strano MS (2006) Optical detection of DNA conformational polymorphism on single-walled carbon nanotubes. Science 311:508–511

Jain KK (2008) Nanomedicine: application of nanobiotechnology in medical practice. Med Princ Pract 17:89–101

Levy F, Colombetti S (2006) Promises and limitations of murine models in the development of anticancer T-cell vaccines. Int Rev Immunol 25:269–295

Lindblad EB (2004) Aluminium adjuvants—in retrospect and prospect. Vaccine 22:3658–3668

Liu Y, Wu DC, Zhang WD, Jiang X, He CB, Chung TS, Goh SH, Leong KW (2005) Polyethylenimine-grafted multiwalled carbon nanotubes for secure noncovalent immobilization and efficient delivery of DNA. Angew Chem Int Ed Engl 44:4782–4785

Luo Y, Wen YJ, Ding ZY, Fu CH, Wu Y, Liu JY, Li Q, He QM, Zhao X, Jiang Y, Li J, Deng HX, Kang B, Mao YQ, Wei YQ (2006) Immunotherapy of tumors with protein vaccine based on chicken homologous Tie-2. Clin Cancer Res 12:1813–1819

Martin CR, Kohli P (2003) The emerging field of nanotube biotechnology. Nat Rev Drug Discov 2:29–37

Mesa C, Fernandez LE (2004) Challenges facing adjuvants for cancer immunotherapy. Immunol Cell Biol 82:644–650

Ni Y, Hu H, Malarkey EB, Zhao B, Montana V, Haddon RC, Parpura V (2005) Chemically functionalized water soluble single-walled carbon nanotubes modulate neurite outgrowth. J Nanosci Nanotechnol 5:1707–1712

Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. Jama 271:907–913

Schirrmacher V (2005) Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother 54:587–598

Sun YP, Fu K, Lin Y, Huang W (2002) Functionalized carbon nanotubes: properties and applications. Acc Chem Res 35:1096–1104

Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356:802–807

Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG Jr, Pinedo HM (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:345–350

Williams KA, Veenhuizen PT, de la Torre BG, Eritja R, Dekker C (2002) Nanotechnology: carbon nanotubes with DNA recognition. Nature 420:761

Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973–4979

Zanello LP, Zhao B, Hu H, Haddon RC (2006) Bone cell proliferation on carbon nanotubes. Nano Lett 6:562–567